Full Text View
Tabular View
No Study Results Posted
Related Studies
12-O-Tetradecanoylphorbol-13-Acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
This study has been completed.
Study NCT00004058   Information provided by National Cancer Institute (NCI)
First Received: December 10, 1999   Last Updated: January 31, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Leukemia
Lymphoma
Myelodysplastic Syndromes
Precancerous/Nonmalignant Condition
Additional conditions recognized in this trial
Bone Marrow Diseases
Disease
Multiple Myeloma
Myelodysplastic-Myeloproliferative Diseases
Myeloproliferative Disorders
Neoplasms
Neoplasms, Plasma Cell
Precancerous Conditions
Preleukemia
Syndrome
More general conditions related to this trial
Blood Protein Disorders
Cardiovascular Diseases
Hematologic Diseases
Hemorrhagic Disorders
Hemostatic Disorders
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms by Histologic Type
Paraproteinemias
Pathologic Processes
Vascular Diseases
Interventions listed in this trial
tetradecanoylphorbol acetate
Sponsors listed in this trial
Cancer Institute of New Jersey
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services